CD47 and cancer: These methodologies used in this study have the potential to help evaluate traditional therapeutic regimens such as chemotherapy and radiotherapy against newer immunomodulation therapies, such as anti-CD47 and anti-PD-L1, to provide clinicians and researchers with a better understanding of anti-cancer drug efficacy.